Track market-moving stories before they get noisy

Algert Global LLC lessened its holdings in shares of Glaukos Corporation (NYSE:GKOS – Free Report) by 43.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 30,871 shares of the medical instruments supplier’s stock after selling 23,330 shares during the quarter. Algert Global LLC owned about 0.05% of Glaukos worth $4,315,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of GKOS. AQR Capital Management LLC lifted its holdings in Glaukos by 2.6% in the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after purchasing an additional 198 shares during the period. Jones Financial Companies Lllp raised its position in shares of Glaukos by 1,405.9% during the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after buying an additional 2,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Glaukos by 41.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after buying an additional 67,668 shares in the last quarter. M&T Bank Corp acquired a new stake in shares of Glaukos in the 2nd quarter worth approximately $203,000. Finally, Gamco Investors INC. ET AL lifted its stake in shares of Glaukos by 10.7% in the 2nd quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock worth $826,000 after acquiring an additional 773 shares during the period. Institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes A number of research analysts recently commented on GKOS shares. Stifel Nicolaus raised their price objective on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Wells Fargo & Company upped their target price on Glaukos from $138.00 to $178.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Needham & Company LLC increased their price target on Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. William Blair reiterated an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. Finally, BTIG Research boosted their price objective on Glaukos from $193.00 to $202.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $178.08.

Read Our Latest Research Report on GKOS Insider Buying and Selling In other news, Director Leana Wen sold 525 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $167.63, for a total transaction of $88,005.75. Following the completion of the sale, the director directly owned 21,092 shares of the company’s stock, valued at $3,535,651.96. This trade represents a 2.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gilbert H. Kliman sold 2,500 shares of Glaukos stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the transaction, the director owned 37,406 shares in the company, valued at $7,107,140. The trade was a 6.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 113,025 shares of company stock worth $19,600,006 over the last quarter. 5.90% of the stock is currently owned by insiders.

Glaukos Stock Up 0.8% NYSE GKOS opened at $181.97 on Friday. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $191.62. The company has a market capitalization of $10.73 billion, a P/E ratio of -55.99 and a beta of 0.78. The company’s 50 day simple moving average is $161.66 and its 200 day simple moving average is $133.63. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46.

Glaukos (NYSE:GKOS – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The firm had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.24) earnings per share. Equities research analysts expect that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year.

Glaukos Company Profile (Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Recommended Stories Five stocks we like better than Glaukos Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far? Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE:GKOS – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 61,957 shares of the medical instruments supplier’s stock, valued at approximately $8,659,000. Deutsche Bank AG owned about 0.11% of Glaukos at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new position in shares of Glaukos during the fourth quarter worth approximately $28,000. Larson Financial Group LLC lifted its position in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares during the period. Parallel Advisors LLC lifted its position in Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 226 shares during the period. Farther Finance Advisors LLC grew its stake in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 215 shares in the last quarter. Finally, CWM LLC grew its stake in Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 143 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Trading Up 0.4% GKOS opened at $185.66 on Monday. The company’s 50 day moving average is $157.38 and its 200-day moving average is $131.72. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $191.62. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The company has a market cap of $10.95 billion, a P/E ratio of -57.13 and a beta of 0.78.

Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm’s revenue was up 49.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.24) EPS. Equities research analysts predict that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year. Analyst Ratings Changes Several brokerages have recently commented on GKOS. Stifel Nicolaus boosted their target price on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Needham & Company LLC increased their price target on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price objective (up from $165.00) on shares of Glaukos in a research note on Thursday, July 30th. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Finally, UBS Group began coverage on Glaukos in a research note on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price for the company. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $178.08.

View Our Latest Stock Analysis on GKOS

Insider Activity at Glaukos In other news, COO Joseph E. Gilliam sold 60,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 2,500 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the transaction, the director owned 37,406 shares of the company’s stock, valued at $7,107,140. The trade was a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 113,025 shares of company stock worth $19,600,006. Corporate insiders own 5.90% of the company’s stock.

Glaukos News Roundup Here are the key news stories impacting Glaukos this week:

Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends. Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale. Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35. Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing Glaukos Company Profile (Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

See Also Five stocks we like better than Glaukos VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Glaukos is scaling iDose TR rapidly, with U.S. glaucoma sales up 64% to $118.5 million. Epioxa is adding a second growth pillar as Corneal Health revenues climbed 48% to $30.4 million.Glaukos raised 2026 revenue guidance to $680-$700 million and gross margin reached about 85%. Glaukos Corporation’s (GKOS - Free Report) growth prospects are supported by the continued expansion of interventional glaucoma, growing clinical and commercial synergies between iDose TR and iStent infinite, and the potential for long-term operating leverage. However, physician workflow challenges, infrastructure constraints and margin pressure remain key risks.

Shares of this Zacks Rank #3 (Hold) company have gained 63.1% so far this year against the industry’s 8.7% decline. The S&P 500 Index has increased 12.6% in the same time frame.

Glaukos, with a market capitalization of $10.95 billion, is a leading ophthalmic medical technology and pharmaceutical company. The company has a trailing four-quarter average earnings surprise of 25.87%.

Image Source: Zacks Investment Research

Positive Factors Driving ProspectsiDose TR Is Rapidly Scaling Into a Major Revenue Engine: Glaukos' iDose TR franchise is rapidly changing the company's revenue profile, with U.S. glaucoma sales rising 64% year over year to $118.5 million in the second quarter and iDose contributing approximately $74 million. The strong adoption reflects growing surgeon interest, expanding trained accounts and increasing utilization across commercial and Medicare Advantage populations.

Management now expects iDose revenues of roughly $275-$280 million in 2026, while maintaining confidence in continued penetration of interventional glaucoma. The platform's growing body of clinical evidence, including 24 peer-reviewed publications and multiple Phase IV studies, should further support physician adoption and establish iDose as an important alternative to chronic topical glaucoma therapy.

Epioxa Launch Opens a New High-Value Growth Opportunity: Epioxa is establishing a second major growth pillar for Glaukos following iDose's rapid commercialization. Corneal Health revenues increased 48% to $30.4 million in the second quarter, including approximately $11 million from Epioxa, despite the product being in the early stages of its launch. Epioxa is the first FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, which offers a differentiated clinical proposition versus legacy epi-off treatment.

Glaukos has already established access pathways covering more than 125 million commercial lives, while its treatment-center network reaches approximately 85% of the U.S. population and is expected to approach 95%. These developments provide substantial infrastructure for accelerating patient adoption.

Higher Sales Outlook and Margin Expansion Look Encouraging: Glaukos is demonstrating meaningful operating leverage as higher-margin iDose and Epioxa products become a larger portion of revenue. The second-quarter consolidated sales increased 50% to $185.6 million, prompting management to raise full-year 2026 revenue guidance to $680-$700 million, $60-$65 million above the previous outlook.

Gross margin reached approximately 85%, up about 90 basis points sequentially, with management expecting additional modest expansion as iDose and Epioxa gain mix share. This combination of rapid top-line growth and favorable product mix should improve the company's earnings profile over time. Management also expects operating expenses of approximately $600 million for 2026 while continuing to invest in commercial infrastructure and R&D.

Diversified Pipeline Boosts Growth Potential: Beyond iDose and Epioxa, Glaukos is developing a broad pipeline across five novel therapeutic platforms, reducing its long-term dependence on any single product. The company is advancing iDose TREX in Phase IIb/III, iDose TRIO toward a targeted 2027 approval, a customized topographically guided iLink therapy toward Phase III, iStent infinite and PRESERFLO MicroShunt programs, and a retinal therapy for wet AMD.

The company also expects to introduce its keratoconus screening device later in 2026. If these programs progress successfully, they could expand Glaukos' addressable markets across glaucoma, corneal disease, retinal disorders and ocular surface conditions, reinforcing its transition toward a diversified ophthalmology platform.

Key ChallengesMedicare Coverage Uncertainty Could Restrict iDose's Potential: The most significant risk to Glaukos' iDose growth trajectory remains Medicare reimbursement and coverage policy. Five of seven Medicare Administrative Contractors issued proposed local coverage determinations during the second quarter. Management has acknowledged meaningful debate ongoing around proposed eligibility criteria and step-edit requirements involving topical drops and selective laser trabeculoplasty.

Although Glaukos expects the final policies to become more favorable, there is no statutory timeline for the next step. A restrictive final LCD could limit physician discretion, delay patient access and reduce the addressable Medicare population. Because iDose is already becoming a major revenue contributor, unfavorable coverage decisions could have an outsized impact on the company's future growth expectations.

Epioxa Could Experience a Temporary Revenue Volatility: Epioxa's commercial trajectory faces a near-term reimbursement transition that could create volatility in reported growth. Its permanent, product-specific J-code became effective July 1, 2026, but management expects providers and its specialty-pharma partner to need time to operationalize the new reimbursement process.

At the same time, the previous Photrexa reimbursement mechanism is being phased out. Management specifically warned that these changes could create uncertainty in the third quarter, potentially disrupting the strong momentum established during the second quarter. Although Glaukos expects the issue to be largely resolved by the fourth quarter, the temporary revenue disruption could make quarterly comparisons less predictable and obscure the underlying pace of Epioxa adoption.

International Glaucoma Growth Faces Headwinds: Glaukos' international glaucoma franchise remains healthy, but its growth outlook incorporates several emerging challenges. International glaucoma revenues increased 17% reportedly and 16% on a constant-currency basis in the second quarter. However, management expects new competitive product trialing to create headwinds across certain major markets.

Reimbursement pressure has emerged in Germany and Switzerland, while foreign-exchange tailwinds are expected to disappear over the second half. Although PreserFlo, iStent infinite and broader MIGS adoption should offset some pressure, the combination of competition, reimbursement changes and less favorable currency translation could moderate international growth. Management nevertheless expects low-to-mid-teens growth for the full year, implying a stronger second-half execution requirement.

Estimate TrendThe Zacks Consensus Estimate for 2026 revenues is pegged at $627.6 million, indicating a 36% improvement from the previous year’s level.

The consensus mark for loss per share is pinned at 35 cents, indicating a 61.1% improvement from the year-ago reported number. The consensus estimate for loss per share has narrowed 38.6% in the past 30 days.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Small-cap stocks are surging, but how you own them matters more than most investors realize.

Key Takeaways Glaukos' adjusted loss narrowed to 14 cents per share as revenues rose 50% YoY to $185.6 million.iDose TR adoption drove U.S. Glaucoma revenues to a record $118.5 million, up 64%.Glaukos raised 2026 sales guidance to $680-$700 million from $620-$635 million. Glaukos Corporation (GKOS - Free Report) reported a second-quarter 2026 adjusted loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 28 cents by 50%. The figure also improved from the year-ago quarter’s adjusted loss of 24 cents per share.

The GAAP loss per share was 31 cents compared with the prior-year quarter’s reported loss of 34 cents.

Shares of GKOS were up 9.8% during after-market trading following the second-quarter results. Year to date, the company’s shares have gained 43.1%, outperforming the industry’s decline of 11.7% and the S&P 500 Index’s increase of 6.6%.

Image Source: Zacks Investment Research

GKOS’ Q2 Revenue PerformanceRevenues of $185.6 million increased 50% year over year on a reported basis and 49% at constant currency (cc). The top line surpassed the Zacks Consensus Estimate by 24.1%.

Growth was driven by increasing adoption and utilization of iDose TR, broader interventional glaucoma initiatives across U.S. and international markets, continued expansion of the company’s global commercial infrastructure and early contributions from the Epioxa launch.

Better-than-expected sales growth led the management to raise its guidance for the full year.

Glaukos Posts Broad Segmental GrowthU.S. Glaucoma revenues reached a record $118.5 million, up 64% year over year on a reported basis. The increase reflected expanding iDose TR adoption, higher utilization among active surgeons and continued growth in trained physicians and accounts.

International Glaucoma revenues were $36.6 million, up 17% year over year on a reported basis. Growth was broad-based, supported by international infrastructure investments and contributions from iStent infinite and PRESERFLO.

Corneal Health revenues increased 48% year over year to $30.4 million. Epioxa contributed approximately $11 million in its first full quarter of commercial availability.

Glaukos’ Margins Expand as Loss NarrowsAdjusted gross profit increased 52.3% year over year to $156.9 million. The adjusted gross margin expanded 150 basis points (bps) to 84.5%.

Selling, general and administrative expenses rose 39.2% year over year to $116.1 million. Research and development expenses totaled $51.3 million, up 40.4% from the prior-year quarter. Total operating expenses were $168.9 million, up 40.8% year over year.

The operating loss narrowed to $17.3 million from $22.7 million in the year-ago period. The adjusted operating loss was $7.6 million, narrower than the prior-year quarter’s adjusted operating loss of $16.6 million.

GKOS Strengthens Its Liquidity PositionGlaukos exited the second quarter with $286.2 million in cash, cash equivalents and short-term investments, up from $280.5 million at the end of the first quarter. The company reported no debt.

Cumulative net cash provided by operating activities was $2.3 million against cumulative net cash used in operating activities of $11.5 million in the year-ago period.

Glaukos Raises 2026 Revenue GuidanceGlaukos raised its 2026 revenue guidance. Management now expects net sales in the range of $680 million to $700 million, up from its previous guidance of $620 million to $635 million. The Zacks Consensus Estimate for the same is pegged at $627.6 million.

The loss per share estimate is pinned at 57 cents, implying a 36.7% improvement year over year.

GKOS Expands Commercial ReachGlaukos continued to broaden iDose TR adoption by expanding its base of trained surgeons and active accounts, increasing utilization and strengthening market access. The therapy is supported by a growing clinical evidence base, including 24 peer-reviewed publications and multiple Phase 4 studies. The company is scaling targeted marketing investments to improve patient awareness and support the shift toward earlier interventional glaucoma care.

GKOS’ Epioxa Access Efforts ProgressThe Epioxa launch progressed through an expanding site-of-care network covering around 85% of the U.S. population, with the potential to reach approximately 95%. Access pathways have been established for more than 125 million commercial lives, including the five largest payers. Its product-specific J-code, J2789, became effective July 1, 2026, which should help streamline reimbursement processes in the second-half of 2026.

Glaukos also launched a co-pay assistance program and operationalized a specialty pharmacy network. Management remains focused on improving diagnosis, referral networks and patient awareness as it transitions commercial activity from Photrexa to Epioxa.

GKOS Advances Its Innovation PipelineGlaukos is advancing iDose TREX through a Phase 2b/3 program and iDose TRIO through a Phase 3b study, with a targeted approval by the end of 2027. The company plans to launch a keratoconus screening device in 2026 and begin a Phase 3 study of its customized, topography-guided iLink therapy in 2027. Other developments include a pivotal study for iStent infinite and PRESERFLO MicroShunt, a Phase 2 demodex blepharitis study with results expected by year-end and the GLK-401 retinal program in wet age-related macular degeneration.

GKOS’ Zacks Rank & Stocks to ConsiderGlaukos has a Zacks Rank #4 (Sell) at present.

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.

McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.

Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management’s expectations.

Chairman and CEO Tom Burns said the company raised its full-year net sales guidance to $680 million to $700 million, up from its prior range of $620 million to $635 million. The company cited continued adoption of iDose TR, the launch of Epioxa, and broad-based international growth as drivers of the stronger outlook.

Get Glaukos alerts:

iDose TR Drives U.S. Glaucoma Growth U.S. glaucoma franchise revenue reached a record $118.5 million in the second quarter, increasing 64% year over year. iDose TR contributed approximately $74 million of that total.

Burns said physician interest and adoption of iDose TR continued to grow, supported by its clinical outcomes and what the company views as a shift toward earlier interventional glaucoma care. Glaukos is focused on adding trained surgeons and active accounts, increasing utilization, expanding market access, and growing clinical evidence for the treatment.

President and COO Joe Gilliam said Glaukos now expects U.S. glaucoma revenue to grow about 50%, plus or minus, for the full year. The company expects its broader U.S. glaucoma portfolio to post at least low-single-digit growth, while iDose TR revenue is expected to land in a range of roughly $275 million to $280 million in 2026.

Gilliam said the second-quarter iDose performance reflected acceleration across Medicare Administrative Contractor regions as well as increased activity among commercial and Medicare Advantage patients. He said the company did not identify material demand pull-forward related to proposed Medicare local coverage determinations, or LCDs.

Five of seven Medicare Administrative Contractors issued proposed LCDs for iDose TR during the quarter. Gilliam said Glaukos was encouraged by support from physicians, medical societies and patients during public meetings and comment periods. He said the company believes the evidence supporting iDose TR should lead to a more favorable final policy if LCDs are finalized.

Earlier in July, CMS issued proposed 2027 rules that, as drafted, largely maintain 2026 ambulatory payment classifications, facility payments and relative physician fee rates for Glaukos procedures in hospital outpatient and ambulatory surgical center settings, Burns said.

International and Corneal Health Performance International glaucoma revenue was $36.6 million, up 17% reported and 16% on a constant-currency basis. Gilliam said Glaukos now expects low- to mid-teens international glaucoma growth for the full year.

Management expects foreign-exchange tailwinds to diminish in the second half. The company also cited competitive product trialing and reimbursement headwinds in Germany and Switzerland, though it expects those factors to be partly offset by growth from PRESERFLO and iStent infinite.

Corneal health revenue rose 48% to $30.4 million, including about $11 million in Epioxa sales. Epioxa is the company’s FDA-approved epithelium-on corneal cross-linking therapy for keratoconus.

Gilliam said Glaukos now expects the overall corneal health franchise to grow approximately 20%, plus or minus, in 2026. He cautioned that third-quarter performance could be volatile as the company transitions from Photrexa and a miscellaneous billing code to Epioxa’s permanent product-specific J-code, which became effective July 1.

“There will be some volatility” during the transition, Gilliam said, though he expects the related issues to begin moving behind the company in the fourth quarter.

O2n systems are deployed at locations serving roughly 85% of the U.S. population, with a pipeline that Glaukos expects could extend reach to approximately 95%. Access pathways for Epioxa have been established for more than 125 million covered commercial lives, including arrangements involving the five largest U.S. payers. Glaukos launched a co-pay assistance program for eligible patients and is investing in awareness, referral networks, earlier diagnosis and patient-support programs. Gilliam said the company has been encouraged by the number of patients being submitted for Epioxa approval, though providers and payers are adjusting to the new permanent J-code. He said some institutions and larger groups are more comfortable using a buy-and-bill model, while many community practices are initially relying more heavily on specialty pharmacy distribution.

Pipeline and Profitability Focus Glaukos said it continues to advance programs across five therapeutic platforms. Its pipeline includes iDose TREX, which is in a Phase II-B/III program; iDose Trio, with a Phase III-B study targeting FDA approval by the end of 2027; and a planned commercial introduction later this year of a keratoconus screening device.

The company also said it is preparing a Phase III program for a third-generation customized topographically guided iLink therapy in 2027. In other programs, Glaukos completed enrollment in a 510(k) pivotal study for PRESERFLO MicroShunt and in a Phase II study for demodex blepharitis, with top-line results from the latter expected by year-end. The company is also advancing a first-in-human study of GLK-401 for wet age-related macular degeneration.

Chief Financial Officer Alex Thurman said the company was pleased with second-quarter progress across gross margin, operating expenses, the bottom line and cash generation. Gross margin was approximately 85% in the quarter, up about 90 basis points sequentially, driven by a greater revenue contribution from iDose TR and Epioxa.

Glaukos maintained its full-year gross-margin target of 84% to 86% and expects modest additional accretion through the remainder of 2026, particularly in the fourth quarter. Thurman said operating expenses are now expected to total around $600 million for the year.

While management sees a clearer path toward profitability as revenue grows, Thurman said Glaukos intends to continue investing in commercialization and clinical development to support its product launches and pipeline, while managing the business toward cash-flow breakeven.

About Glaukos (NYSE:GKOS)Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Glaukos Right Now?Before you consider Glaukos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.

While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Glaukos (GKOS - Free Report) reported $185.61 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 49.5%. EPS of -$0.14 for the same period compares to -$0.24 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $149.57 million, representing a surprise of +24.1%. The company delivered an EPS surprise of +50%, with the consensus EPS estimate being -$0.28.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Glaukos performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues by geography- United States: $146.74 million compared to the $112.26 million average estimate based on four analysts. The reported number represents a change of +62.1% year over year.Revenues by product category- United States- Glaucoma: $118.5 million versus $96.27 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +63.9% change.Revenues by product category- International- Corneal Health: $2.24 million compared to the $2.64 million average estimate based on four analysts. The reported number represents a change of -4.7% year over year.Revenues by geography- International: $38.87 million versus the four-analyst average estimate of $37.05 million. The reported number represents a year-over-year change of +15.7%.Revenues by product category- International- Glaucoma: $36.63 million versus $34.41 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +17.2% change.Revenues by product category- United States- Corneal Health: $28.19 million versus the four-analyst average estimate of $15.98 million. The reported number represents a year-over-year change of +54.6%.Net Sales- Corneal Health: $30.43 million compared to the $19.2 million average estimate based on five analysts. The reported number represents a change of +47.8% year over year.Net Sales- Glaucoma: $155.2 million compared to the $130.55 million average estimate based on five analysts. The reported number represents a change of +49.9% year over year.View all Key Company Metrics for Glaukos here>>>

Shares of Glaukos have returned +8.3% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

17.91K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Posted by Defense World Staff on Jul 26th, 2026

Bank of New York Mellon Corp reduced its stake in shares of Glaukos Corporation (NYSE:GKOS – Free Report) by 3.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 343,173 shares of the medical instruments supplier’s stock after selling 12,667 shares during the period. Bank of New York Mellon Corp owned approximately 0.58% of Glaukos worth $36,946,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in Glaukos by 10.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after purchasing an additional 336,266 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Glaukos by 49.8% in the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock valued at $381,289,000 after purchasing an additional 1,123,140 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Glaukos by 183.4% during the fourth quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock worth $340,855,000 after buying an additional 1,953,578 shares in the last quarter. State Street Corp grew its holdings in shares of Glaukos by 0.9% during the fourth quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier’s stock worth $239,640,000 after buying an additional 18,040 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in shares of Glaukos by 3.5% during the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after buying an additional 68,497 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insiders Place Their Bets In other news, Director Leana Wen sold 1,700 shares of Glaukos stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the completion of the transaction, the director directly owned 19,739 shares in the company, valued at approximately $2,829,585.65. The trade was a 7.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director directly owned 35,528 shares in the company, valued at $5,000,921.28. The trade was a 12.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,273 shares of company stock worth $8,882,003 in the last three months. 5.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes Several research firms have commented on GKOS. JPMorgan Chase & Co. boosted their target price on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Wells Fargo & Company lifted their price objective on shares of Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Stifel Nicolaus boosted their price objective on shares of Glaukos from $170.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Citigroup increased their target price on shares of Glaukos from $162.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Friday, July 17th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus target price of $154.85.

Read Our Latest Report on Glaukos

Glaukos Stock Performance NYSE GKOS opened at $153.40 on Friday. The firm has a market capitalization of $9.01 billion, a P/E ratio of -46.77 and a beta of 0.75. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. The firm’s fifty day moving average price is $135.85 and its two-hundred day moving average price is $123.44. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $161.53.

Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The company had revenue of $150.57 million during the quarter, compared to the consensus estimate of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The company’s quarterly revenue was up 41.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.22) EPS. As a group, research analysts anticipate that Glaukos Corporation will post -0.57 EPS for the current year.

About Glaukos (Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Featured Articles Five stocks we like better than Glaukos Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of New York Mellon Corp Has $40.44 Million Stock Holdings in Qorvo, Inc. $QRVO

NEXT HEADLINE »Bank of Nova Scotia Raises Holdings in American Tower Corporation $AMT

Should you stick with a diversified healthcare titan or a specialized high-growth challenger? Here is how Abbott Laboratories (ABT 0.70%) and Glaukos (GKOS +1.53%) stack up for investors looking ahead into 2026.

Abbott operates as a global leader across diagnostics, nutrition, and medical devices, offering stability through its massive scale. Glaukos focuses on ophthalmic solutions, aiming to disrupt the way doctors treat glaucoma and corneal diseases. Both compete for space among medical device stocks but offer very different risk and reward profiles.

The case for Abbott LaboratoriesAbbott is a diversified healthcare leader selling medical devices, diagnostic tools, nutritional products, and generic medicines. Its portfolio includes high-growth areas like diabetes care and cardiovascular solutions. As of March 2026, the company expanded its presence in oncology by acquiring Exact Sciences for $23 billion. This acquisition integrated new cancer diagnostics technology into the existing Diagnostic Products segment. Abbott does not rely on any single customer for a material portion of its revenue, which helps reduce the risk of a sudden loss of business.

In FY 2025, revenue reached $44.3 billion, representing growth of roughly 5.5% compared to the previous year. The company reported net income of close to $6.5 billion for the same period. This resulted in a net margin of 14.7%. While revenue has grown steadily, this net margin was lower than the 31.9% recorded in 2024, reflecting the costs associated with its large-scale business shifts and recent acquisitions.

Its current, the debt-to-equity ratio is approximately 0.65x. This ratio measures total debt relative to shareholders’ equity, with lower ratios indicating less reliance on borrowed money. Free cash flow, which is the cash left after paying for capital expenditures, was nearly $7.4 billion for the fiscal 2025.

The case for GlaukosGlaukos is a specialist in the ophthalmic medical technology market, focusing on therapies for glaucoma and retinal diseases. The company generates revenue primarily from ophthalmic surgeons and surgical centers rather than a few large distributors. No single customer accounts for more than 10% of total net sales. While it operates globally, roughly 75% of its 2025 sales came from the United States. The company is betting heavily on its iStent and iDose platforms to capture a larger share of the vision care market.

For FY 2025, Glaukos reported revenue of $507.4 million, representing a 32% year-over-year increase. Despite this rapid top-line expansion, the company reported a net loss of approximately $187.7 million The company continues to prioritize growth and research over immediate profitability.

The current debt-to-equity ratio was roughly 0.16x. Free cash flow was negative at approximately $22.5 million, as the company spent more on operations and capital investments than it generated in cash.

Risk profile comparisonAbbott faces persistent legal exposure, including securities class actions regarding FDA compliance failures. It also deals with civil litigation related to infant formula facilities and product liability lawsuits involving spinal cord stimulators. Integrating the $23 billion Exact Sciences acquisition adds operational complexity and increased debt. Furthermore, the company must invest heavily in cybersecurity following previous data breaches to protect its sensitive customer information.

Glaukos relies heavily on its San Clemente, California, campus to manufacture its main product lines. Any disruption at this single location could severely impair its ability to supply customers. The company also depends on reimbursement levels from Medicare and private payers, making it vulnerable to changes in government coding or payment rates. Finally, Glaukos faces stiff competition from much larger and better-capitalized firms such as AbbVie (ABBV 0.75%) and Alcon Inc (ALC 0.46%).

Valuation comparisonAbbott looks significantly cheaper on a Forward P/E basis, while Glaukos maintains a much higher P/S ratio as investors price in its rapid growth potential.

MetricAbbott LaboratoriesGlaukosSector BenchmarkForward P/E17.4x2,000x389.1xP/S ratio3.7x15.5xSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Abbott Labs's recent quarterly results and its guidance for fiscal 2026 presented investors with a mixed bag. The Medical Device segment, led by cardiovascular devices, brought solid growth, but Abbott is seeing a slowdown in new users for its glucose monitoring system FreeStyle Libre CGM. The Nutrition business continues to show weakness as Abbott discounts prices to increase volume.

Abbott’s strengths are that Exact Sciences adds a cancer screening arm, and folds in the popular Cologuard product to its portfolio. Abbott should be able to power sales outside the U.S. for Cologuard. For 2026, Abbott should get company-wide sales over $50 billion, which would be about 13% year-over-year growth.

Glaukos has been pioneering treatment for glaucoma and other eye disorders, developing micro-invasive glaucoma surgery (MIGS) early in this decade. MIGS is now a standard globally. Investors are especially excited about a new product that just came to market this year called Epioxa. It’s an incision-free alternative to treating keratoconus, a rare, sight-threatening disease. The potential is huge—by 2030, Glaukos believes it could be used on 18,000 eyes, bringing in more than $1 billion in revenue.

For 2026, iDose continues to power the business with excellent U.S. growth. Analysts see sales rising almost 25% to $630 million, with a narrowing of the net loss to about $56 million.

The choice here is between a health care giant hoping to buy its way to growth and a diagnostic startup that has revolutionized one area of treatment and looks set to do the same for a second. Glaukos comes at a premium. But its fast growth means long-term investors should be getting good value in the long run.

Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.

©2026 Investor’s Business Daily, LLC. All Rights Reserved.

© Chaay_Tee / iStock via Getty Images

Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you can bet that any company that reports earnings that miss the mark or gives guidance less than expected could get hit hard. The Dow Jones Industrials hit yet another all-time high last Thursday, closing the session at 52,900, up 1.14%, while the S&P 500 closed essientially flat at 7,482, up 0.01%. The Nasdaq took another hit Thursday as sellers returned for the rotation trade, with chip stocks tagged again, and closed the day at 25,832, down 0.80%. The small-cap heavy Russell 2000 also closed lower to end the week, down 0.55% at 2,996.

Treasury Bonds: Yields were mixed across the Treasury curve on Thursday as buyers continued to load up on the short end and belly of the curve, while some selling came in on the long end. The non-farm payroll report came in much lower than anticipated, at 57,000 versus expectations of 110,000, and unemployment ticked lower to 4.2%. Worries about rate hikes later this year finally took a back seat, at least for the time being. The 30-year-long bond closed the session at 4.99%, while the 10-year note closed at 4.49%. 

Oil and Gas: Oil prices closed mixed on Thursday as ships continue to pass through the Strait of Hormuz unimpeded and supplies worldwide are finally returning closer to normal. When the final trades came in on Thursday, Brent Crude was basically unchanged at $71.59, while West Texas Intermediate closed lower at $68.46, down 0.17%. Natural gas, which has been strong recently, closed down 0.34% at $3.21. 

Gold: After a dreadful month of June and the second quarter, Gold continues to show signs of life. Thursday, the precious metal closed higher by 2.27% at $4,121, while Silver also continued to run higher, closing the session up 3.15% at $60.83. The declining chances of a rate hike gave the precious metals complex a tailwind on Thursday, and it is likely to continue this week. 

Crypto: Cryptocurrencies surged on Thursday, with Bitcoin reclaiming the $61,000 level and clawing back some of its losses from the previous week. The broader market got a lift after a softer-than-expected U.S. jobs report and comments signaling easing inflation have helped calm rate-hike concerns, reigniting investor appetite for digital assets. At 8 AM EDT, Bitcoin traded at $62,840, while Ethereum traded at $1,770.

24/7 Wall St. reviews dozens of analyst research reports every day to identify fresh investment ideas for investors and traders alike. These daily analyst notes include recommendations on stocks to buy, sell, or avoid, as well as new coverage initiations. Important reminder: No single analyst report should ever be the sole basis for buying or selling a stock.

Here are some of the best Wall Street analyst upgrades, downgrades, and initiations seen on Monday, July 6, 2026.  

Upgrades: Agnico Eagle Mines (NYSE: AEM | AEM Price Prediction) was upgraded to Buy from Hold at Jefferies. which moved the price target for the shares up to $200 from $187. Gilead Sciences (NASDAQ: GILD) was upgraded to Buy from Hold at HSBC, which lifted the target price for the shares to $155 from $133. Okta (NASDAQ: OKTA) was upgraded to Putperform from Sector Perform at Scotiabank, with a $165 target price. T-Mobile US (NASDAQ: TMUS) was upgraded to Buy from Hold at Bank of America, with a $220 target price. U.S. Bancorp (NYSE: USB) was raised to Buy from Hold at Jefferies, and boosted the target price for the stock to $75 from $60. Downgrades: Datadog (NASDAQ: DDOG) was downgraded to Market Perform from Outperform at Bernstein, which raised the price target to $226 from $180. Delta Air Lines (NYSE: DAL) was cut to Outperform from Strong Buy at Raymond James, which lifted the target price for the stock to $104 from $80. JetBlue Airways (NASDAQ: JBLU) was downgraded to Underperform from Market Perform at Raymond James, without a price target. Pfizer (NYSE: PFE) was cut to Hold from Buy at HSBC, which trimmed the target price for the pharmaceutical giant to $28 from $32. Regions Financial (NYSE: RF) was cut to Underperform from Neutral at Baird, with a $28 target price. Initiations: ERock (NYSE: EROC) was initiated with an Outperform rating at Evercore ISI, with a $28 target price. JPMorgan started the shares with an Overweight rating and a $28 target, while Morgan Stanley initiated the stock with an Overweight rating and a $21 target price. The company was a recent IPO. Glaukos (NYSE: GKOS) was started with a Buy rating at H.C. Wainwright, with a $168 target price. NRG Energy (NYSE: NRG) was initiated with a Buy rating at Siebert Williams, with a $184 target price. 
Parabilis Medicines (NASDAQ: PBLS) was initiated with a Buy rating at Bank of America, with a $45 target price. Whitehawk Minerals (NYSE: WHK) was initiated with a Buy rating at Stifel, with a $30 target price for the shares. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and T-Mobile US didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.

Glaukos Corporation (NYSE: GKOS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have issued a buy recommendation and one has

Glaukos Corporation (NYSE: GKOS - Get Free Report) CFO Alex Thurman sold 2,511 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the sale, the chief financial officer directly owned 41,967

Glaukos (NYSE: GKOS - Get Free Report) and Anteris Technologies Global (NASDAQ: AVR - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Volatility and Risk Glaukos has a beta of

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 10-13, 2026 in Washington, D.C. Glaukos will be exhibiting onsite at booth #407.

-

New J-code for Epioxa™, J2789, set to become effective July 1, 2026

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ (“Epioxa”) for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated.

The new J-code for Epioxa, J2789, is set to become effective July 1, 2026. It is expected to streamline the reporting and payment of Epioxa by U.S. payers over time, and has been published here on the CMS website.

“The assignment of a product-specific J-code for Epioxa represents an important milestone, supporting our market access initiatives to increase access and expand coverage for patients suffering from keratoconus,” said Thomas Burns, Glaukos chairman and chief executive officer. “Once effective, this new J-code is expected to enable more streamlined and consistent coverage and payment for Epioxa over time, strengthening the foundation for our commercial launch and enabling broader patient access.”

J-codes are reported by U.S. healthcare providers and used by U.S. government and commercial payers to streamline the billing and reimbursement process for pharmaceuticals, such as Epioxa, administered by a healthcare professional.

Epioxa represents a transformative innovation in keratoconus care, offering an incision-free alternative to traditional corneal cross-linking procedures as it does not require the removal of the corneal epithelium, the outermost layer of the front of the eye. This novel, oxygen-enriched topical therapeutic, bioactivated by UV light, is designed to eliminate the pain associated with removal of the epithelium, streamline the procedure, and minimize recovery, all while delivering clinically meaningful outcomes and exceptional value to patients, providers, and the healthcare system.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

About Epioxa HD / Epioxa

Indication: EPIOXA™ HD (riboflavin 5’-phosphate ophthalmic solution) 0.239% and EPIOXA™ (riboflavin 5’-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n™ System and the Boost Goggles®.

Dosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use. EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only. Refer to the O2n System Operator’s Manual and Boost Goggles User Guide for device instructions.

Contraindications: EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.

Warnings and Precautions: Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.

Adverse Reactions: The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.

For more information, visit www.glaukos.com.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which we obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, the continued efficacy and safety profile of our products, and the extent to which this new J-code will enable more streamlined and consistent coverage and payment for Epioxa over time. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 23, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

More News From Glaukos Corporation

Back to Newsroom

Key Takeaways Glaukos gains CMS J-code J2789 for Epioxa, effective July 1, 2026, boosting reimbursement clarity.GKOS expects improved market access, simplified billing and broader payer coverage over time.Epioxa offers a non-invasive, oxygen-enriched therapy designed to reduce pain and recovery time. Glaukos (GKOS - Free Report) announced that its innovative keratoconus treatment, Epioxa (Epioxa HD / Epioxa), was assigned a permanent HCPCS J-code — J2789 — by the U.S. Centers for Medicare and Medicaid Services (“CMS”).

The J-code becomes effective from July 1, 2026, and is expected to streamline how Epioxa is reported and reimbursed by U.S. payers over time.

Per management, the new product-specific J-code for Epioxa is an important step in improving market access, helping expand coverage for keratoconus patients. Once active, this new J-code should simplify reimbursement, strengthen the foundation of commercial launch and improve patient access over time.

Likely Trend of GKOS Stock Following the NewsFollowing the announcement, GKOS shares gained 0.4% at yesterday’s closing. In the year-to-date period, shares of the company have climbed 7.1% against the industry’s 11.6% decline. However, the S&P 500 has risen 1.9% during the same time frame.

In the long run, the J-code assignment for Epioxa positions Glaukos for a scalable growth trajectory. With streamlined reimbursement and improved payer clarity, the company can drive broader physician adoption and patient access. This milestone reduces administrative friction, enhances commercial execution and supports predictable revenue expansion. Coupled with Epioxa’s differentiated, non-invasive profile, Glaukos is well-positioned to strengthen its leadership in corneal therapies and deliver sustained growth in the keratoconus treatment landscape.

GKOS currently has a market capitalization of $7 billion.

Image Source: Zacks Investment Research

More on the NewsEpioxa itself represents a breakthrough in keratoconus treatment, providing an incision-free alternative to traditional corneal cross-linking by preserving the corneal epithelium. This oxygen-enriched, UV-activated topical therapy is designed to reduce pain, streamline the procedure and shorten recovery time, while delivering strong clinical results and value.

J-codes are used by U.S. healthcare providers to report treatments, and by government and commercial payers to simplify billing and reimbursement for physician-administered drugs like Epioxa. With the assignment of J2789, Glaukos is well-positioned to improve coverage consistency and reduce administrative friction for providers treating keratoconus.

Industry Prospects Favoring the MarketGoing by the data provided by Research Nester, the keratoconus treatment market is valued at $584.6 million in 2026 and is expected to witness a CAGR of 4.2% through 2035.

Factors like the rising prevalence of keratoconus, increased awareness of advanced non-invasive treatment, rising geriatric population and the continuous advancement of diagnostic technologies are boosting the market’s growth.

Other NewsIn January, Glaukos announced the FDA approval for the company’s NDA labeling supplement, permitting unlimited re-administration of iDose TR in eligible patients. This approval expands the product’s treatment flexibility and reinforces confidence in its long-term therapeutic profile.

GKOS’ Zacks Rank & Stocks to ConsiderCurrently, GKOS has a Zacks Rank #4 (Sell).

Some better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Phibro Animal Health (PAHC - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .

Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, 36.8% narrower than the Zacks Consensus Estimate. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rankstocks here.

PACB has an estimated earnings recession rate of 1.9% compared with the industry’s 12.9% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.

Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

GE HealthCare Technologies, currently carrying a Zacks Rank #2, reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.

GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12.1% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.

Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.